• BigBear Pharma: Capmatinib (Campmadx) Product Update Announcement

  Dear Customers, Partners, and Relevant Parties:BigBear Pharma's Capmatinib uses a light yellow coating powder for film coating. To further optimiz···【Read More】

  Update: 26 Oct,2026Source: Haiou HealthViews: 104

• FDA Approves Evoxac (cevimeline HCl) Oral Solution for Dry Mouth Symptoms Associated with Sjögren’s Disease in Adults

  On October 20, 2026, local time, Cosette announced that the U.S. FDA has approved Evoxac(cevimeline HCl) oral solution for the treatment of dry mouth ···【Read More】

  Update: 23 Oct,2026Source: Haiou HealthViews: 113

• U.S. FDA Approves Hovilpri (pritelivir) for the Treatment of Refractory Mucocutaneous HSV Lesions in Immunocompromised Adults

  On October 10, 2026, local time, the U.S. FDA approved Hovilpri (pritelivir) 100 mg tablets for the treatment of mucocutaneous lesions caused by herpe···【Read More】

  Update: 21 Oct,2026Source: Haiou HealthViews: 122

• Anktiva Indication Expanded! U.S. FDA Approves It for Treatment of Some Patients with BCG-Unresponsive Bladder Cancer

  Recently, the U.S. Food and Drug Administration (FDA) expanded the approved indication for Anktiva (nogapendekin alfa inbakicept-pmln) in combination ···【Read More】

  Update: 19 Oct,2026Source: Haiou HealthViews: 125

• BigBear Pharma: Enasidenib (Enasidenib, ENASIDX) 50mg Product Update Notice

  Dear Customers, Partners, and Relevant Units:BigBear Pharma's Enasidenib is film-coated using yellow coating powder. To further optimize supply ch···【Read More】

  Update: 15 Oct,2026Source: Haiou HealthViews: 133

• Telisotuzumab Adizutecan (Temab-A) Receives Two U.S. FDA Breakthrough Therapy Designations for CRC and NSCLC

  On October 7, 2026, local time, AbbVie announced that the U.S. FDA has granted telisotuzumab adizutecan (Temab-A; ABBV-400) two breakthrough therapy d···【Read More】

  Update: 13 Oct,2026Source: Haiou HealthViews: 156

• BigBear Pharma: Product Update Notice for Deucravacitinib (DUVACIDX)

  Dear Customers, Partners and Relevant Parties,Deucravacitinib (DUVACIDX) manufactured by BigBear Pharma uses pink coating powder for film coating. To ···【Read More】

  Update: 12 Oct,2026Source: Haiou HealthViews: 142

• Study Suggests Laughter May Help Treat Chronic Obstructive Pulmonary Disease (COPD)

  A new study indicates that for patients with chronic obstructive pulmonary disease (COPD), “laughter therapy” is comparable to the classic “pursed-lip···【Read More】

  Update: 20 Sep,2026Source: Haiou HealthViews: 211

• Analysis of First-Line EGFR Medications for Non-Small Cell Lung Cancer: Based on the NCCN Clinical Practice Guidelines in Oncology (NSCLC, Version 1.2026)

  Application Note: This content is compiled based on the NCCN Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer (Version 1.2026),···【Read More】

  Update: 17 Sep,2026Source: Haiou HealthViews: 278

• U.S. FDA Approves Ameluz Red-Light PDT for the Treatment of Superficial Basal Cell Carcinoma

  On September 14, 2026, local time, Biofrontera Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug ···【Read More】

  Update: 17 Sep,2026Source: Haiou HealthViews: 244

• FDA Approves Isembyld (apitegromab-mstn) Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

  Recently, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca's Etcamah (camizestrant) in combination with···【Read More】

  Update: 15 Sep,2026Source: Haiou HealthViews: 225

• BigBear Pharma: Statement on the Investigation into Quality Defects of Sealing Stickers on Certain Drug Products

  Dear Customers, Partners, and Relevant Parties,During a recent product quality inspection bigbear pharma discovered that the sealing stickers used on ···【Read More】

  Update: 10 Sep,2026Source: Haiou HealthViews: 196

• Remibrutinib Significantly Reduces Relapse Rate and Shows Favorable Safety in Phase III Trial for New Indication in Relapsing Multiple Sclerosis (RMS)

  On September 1, 2026, local time, Novartis announced positive topline results from the Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib in rel···【Read More】

  Update: 07 Sep,2026Source: Haiou HealthViews: 246

• Zanvastro (zilganersen) Approved in the U.S. for the Treatment of Rare Alexander Disease

  On September 3, 2026, the U.S. Food and Drug Administration (FDA) approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in···【Read More】

  Update: 04 Sep,2026Source: Haiou HealthViews: 195

• Selpercatinib (SEPADX) manufactured by BigBear Pharma has received approval in Laos

  Vientiane, Laos - November 20, 2023 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer ···【Read More】

  Update: 18 Aug,2026Source: Haiou HealthViews: 210